Filing Details

Accession Number:
0000899243-21-039704
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-10-08 16:33:08
Reporting Period:
2021-10-06
Accepted Time:
2021-10-08 16:33:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1689548 Praxis Precision Medicines Inc. PRAX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1070844 A Stephen Schwarzman C/O Blackstone Inc.
345 Park Avenue
New York NY 10154
No No Yes No
1393818 Blackstone Inc 345 Park Avenue
New York NY 10154
No No Yes No
1404071 L.l.c. Management Group Blackstone C/O Blackstone Inc.
345 Park Avenue
New York NY 10154
No No Yes No
1464694 L.p. I Holdings Blackstone C/O Blackstone Inc.
345 Park Avenue
New York NY 10154
No No Yes No
1464695 L.l.c. Gp I/Ii Holdings Blackstone C/O Blackstone Inc.
345 Park Avenue
New York NY 10154
No No Yes No
1484870 L.p. Ii Holdings Blackstone C/O Blackstone Inc.
345 Park Avenue
New York NY 10154
No No Yes No
1728529 L.l.c. Associates Opportunity Strategic Blackstone C/O Blackstone Inc.
345 Park Avenue
New York NY 10154
No No Yes No
1728531 L.l.c. Solutions Alternative Blackstone C/O Blackstone Inc.
345 Park Avenue
New York NY 10154
No No Yes No
1736665 L.p. Fund Master Parallel Bsof C/O Blackstone Inc.
345 Park Avenue
New York NY 10154
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-10-06 400,000 $17.50 0 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 4,894,109 Indirect See Footnotes
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.50 to $18.48, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price in the range set forth in this footnote.
  2. Reflects securities held directly by BSOF Parallel Master Fund L.P. Blackstone Strategic Opportunity Associates L.L.C. is the general partner of BSOF Parallel Master Fund L.P. Blackstone Holdings II L.P. is the sole member of Blackstone Strategic Opportunity Associates L.L.C. Blackstone Alternative Solutions L.L.C. is the investment manager of BSOF Parallel Master Fund L.P. Blackstone Holdings I L.P. is the sole member of Blackstone Alternative Solutions L.L.C.
  3. Reflects securities held directly by Clarus Lifesciences III, L.P. Clarus Ventures III GP, L.P. is the general partner of Clarus Lifesciences III, L.P. Blackstone Clarus III L.L.C. is the general partner of Clarus Ventures III GP, L.P. The sole member of Blackstone Clarus III L.L.C. is Blackstone Holdings II L.P.
  4. The general partner of each of Blackstone Holdings I L.P. and Blackstone Holdings II L.P. is Blackstone Holdings I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP L.L.C. is Blackstone Inc. The sole holder of the Series II preferred stock of Blackstone Inc. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by Blackstone's senior managing directors and controlled by its founder, Stephen A. Schwarzman.
  5. Information with respect to each of the Reporting Persons is given solely by such Reporting Person, and no Reporting Person has responsibility for the accuracy or completeness of information supplied by another Reporting Person.
  6. Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.